RAMP3 and hepatocellular carcinoma: Furthermore, we found that RAMP3 was associated with idarubicin, which has been shown to improve remission rates in intermediate stage hepatocellular carcinoma (49), suggesting the possibility that RAMP3, like other small molecule drugs (50) being investigated, could be a new drug target.